Avidity Biosciences, Inc. RNA
Institutional shares held
107 Million
224K
calls
161K
puts
Total value of holdings
$4.43B
$9.25M
calls
$6.67M
puts
Market Cap
$2.16B
52,127,000
Shares Out.
Institutional ownership
205.48%
# of Institutions
256
We take great care to ensure that the data presented and summarized in this overview for Avidity Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RNA
View all-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$440 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.23MShares$382 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$357 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$336 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$291 Million0.06% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.88MShares$284 Million4.75% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.3MShares$261 Million4.04% of portfolio
-
Janus Henderson Group PLC London, X04.9MShares$202 Million0.12% of portfolio
-
State Street Corp Boston, MA4.71MShares$195 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.08MShares$127 Million0.26% of portfolio
Latest Institutional Activity in RNA
Top Purchases
Top Sells
About RNA
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Insider Transactions at RNA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 19
2024
|
Arthur A Levin Director |
SELL
Open market or private sale
|
Direct |
3,323
-18.31%
|
$139,566
$42.12 P/Share
|
|
Nov 19
2024
|
Arthur A Levin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,323
+15.47%
|
$3,323
$1.24 P/Share
|
|
Nov 18
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
25,000
-21.01%
|
$1,025,000
$41.14 P/Share
|
|
Nov 18
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+17.36%
|
$350,000
$14.22 P/Share
|
|
Nov 06
2024
|
Michael F Mac Lean Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
106,319
-25.41%
|
$4,784,355
$45.63 P/Share
|
|
Nov 06
2024
|
Michael F Mac Lean Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
79,057
+20.21%
|
$553,399
$7.7 P/Share
|
|
Oct 21
2024
|
Arthur A Levin Director |
SELL
Open market or private sale
|
Direct |
5,000
-25.21%
|
$230,000
$46.63 P/Share
|
|
Oct 21
2024
|
Arthur A Levin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+20.14%
|
$5,000
$1.24 P/Share
|
|
Oct 16
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
25,000
-21.01%
|
$1,200,000
$48.52 P/Share
|
|
Oct 16
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+17.36%
|
$350,000
$14.22 P/Share
|
|
Oct 07
2024
|
Tamar Thompson Director |
SELL
Open market or private sale
|
Direct |
30,000
-100.0%
|
$1,320,000
$44.98 P/Share
|
|
Oct 07
2024
|
Tamar Thompson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+50.0%
|
$810,000
$27.63 P/Share
|
|
Oct 01
2024
|
W. Michael Flanagan CSTO |
SELL
Open market or private sale
|
Direct |
62,500
-42.26%
|
$2,937,500
$47.62 P/Share
|
|
Oct 01
2024
|
W. Michael Flanagan CSTO |
BUY
Exercise of conversion of derivative security
|
Direct |
62,500
+29.71%
|
$1,625,000
$26.75 P/Share
|
|
Sep 23
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
13,153
-16.01%
|
$578,732
$44.0 P/Share
|
|
Sep 23
2024
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
32,880
-12.29%
|
$1,446,720
$44.0 P/Share
|
|
Sep 23
2024
|
W. Michael Flanagan CSTO |
SELL
Open market or private sale
|
Direct |
25,000
-13.75%
|
$1,075,000
$43.95 P/Share
|
|
Sep 23
2024
|
Michael F Mac Lean Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,510
-10.67%
|
$506,440
$44.0 P/Share
|
|
Sep 19
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+22.17%
|
-
|
|
Sep 19
2024
|
Sarah Boyce President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+18.16%
|
-
|
Last 12 Months Summary
Buy / Acquisition
2.54M
Shares
From
13
Insiders
| Grant, award, or other acquisition | 697K shares |
|---|---|
| Exercise of conversion of derivative security | 1.27M shares |
| Bona fide gift | 22.5K shares |
| Other acquisition or disposition | 550K shares |
Sell / Disposition
2.16M
Shares
From
8
Insiders
| Open market or private sale | 1.59M shares |
|---|---|
| Bona fide gift | 22.5K shares |
| Other acquisition or disposition | 550K shares |